

BioMarin to Present at the Baird Growth Stock Conference

PRNewswire-FirstCall

NOVATO, Calif

BioMarin Pharmaceutical Inc. (Nasdaq and SWX: BMRN) announced today that Stephen Aselage, Senior Vice President of Global Commercial Development of BioMarin, will present a company update at the Baird Growth Stock Conference in Chicago on Tuesday, May 13, 2008 at 7:45 a.m. CT.

Interested parties may access a live audio webcast of the presentation via the investor section of the BioMarin website, <http://www.bmrn.com/>. A replay of the presentation will be archived on the site for at least one week following the presentation.

About BioMarin

BioMarin develops and commercializes innovative biopharmaceuticals for serious diseases and medical conditions. The company's product portfolio comprises three approved products and multiple clinical and preclinical product candidates. Approved products include Naglazyme(R) (galsulfase) for mucopolysaccharidosis VI (MPS VI), a product wholly developed and commercialized by BioMarin; Aldurazyme(R) (laronidase) for mucopolysaccharidosis I (MPS I), a product which BioMarin developed through a 50/50 joint venture with Genzyme Corporation; and Kuvan(R) (sapropterin dihydrochloride) Tablets, a product for the treatment of phenylketonuria (PKU), developed in partnership with Merck Serono, a division of Merck KGaA of Darmstadt, Germany. Other product candidates include 6R-BH4 for cardiovascular indications, which is currently in Phase 2 clinical development for the treatment of peripheral arterial disease and sickle cell disease, and

PEG-PAL (PEGylated recombinant phenylalanine ammonia lyase) for the treatment of PKU. For additional information, please visit www.BMRN.com. Information on BioMarin's website is not incorporated by reference into this press release.

BioMarin(R), Naglazyme(R) and Kuvan(R) are registered trademarks of BioMarin Pharmaceutical Inc.

Aldurazyme(R) is a registered trademark of BioMarin/Genzyme LLC.

Contacts:

Investors

Eugenia Shen

BioMarin Pharmaceutical Inc.

(415) 506-6570

Media

Susan Berg

BioMarin Pharmaceutical Inc.

(415) 506-6594

First Call Analyst:

FCMN Contact: eshen@bmrn.com

SOURCE: BioMarin Pharmaceutical Inc.

CONTACT: Investors, Eugenia Shen, +1-415-506-6570, or Media, Susan Berg, +1-415-506-6594, both of BioMarin Pharmaceutical Inc.

Web site: <http://www.bmrn.com/>

<https://investors.biomin.com/2008-05-06-BioMarin-to-Present-at-the-Baird-Growth-Stock-Conference>